Navigation Links
diaDexus Announces FDA Clearance for New Automated PLAC Test
Date:1/7/2011

SOUTH SAN FRANCISCO, Calif., Jan. 7, 2011 /PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared for marketing the automated version of its proprietary PLAC® Test. This PLAC Test product format, based on turbidimetric immunoassay (TIA) technology, is designed to run on most clinical chemistry analyzers, significantly expanding the number of clinical labs and physician offices that are able to offer the PLAC Test.

"We are pleased to have this format of our PLAC Test cleared by the FDA. This new automated TIA version addresses the heterophilic interference found in the previous version. We expect to launch the new version of the PLAC Test next quarter," said Patrick Plewman, president and chief executive officer of diaDexus.

About diaDexus, Inc.

diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. For more information, please visit the company's website at www.diaDexus.com

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products and other statements that are not historical in nature, particularly those that use terminology such as "will," "potential", "could," "can," "believe," "intends," "continue," "plans," "expects," "estimates" or comparable terminology. Forward-looking statements are based on current expectations and assumptions, and entail various known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to diaDexus that could cause actual results to differ materially from those expressed in such forward-looking statements include diaDexus' ability to reintroduce its PLAC TIA product; diaDexus' ability to demonstrate that treatment of individuals based on their Lp-PLA2 levels improves clinical outcomes in prospective clinical studies; the rate of adoption of the PLAC Test by doctors and laboratories; the insurance payer community's acceptance of and reimbursement for the PLAC Test; diaDexus' reliance on sole source third party manufacturers to manufacture and supply its main reagent and the PLAC Test, including the TIA format; its ability to retain key employees and to attract, retain and motivate other qualified personnel; diaDexus' limited revenue and cash resources; and diaDexus' significant corporate expenses, including expenses associated with being a public company. Additional factors that could cause diaDexus' results to differ materially from those described in the forward-looking statements can be found in diaDexus' most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at www.sec.gov. The information set forth herein speaks only as of the date hereof, and diaDexus disclaims any intention and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. diaDexus to Present at the Canaccord Genuity Healthcare Conference
2. diaDexus, Inc. Reports 2010 Third Quarter Financial Results
3. diaDexus, Inc. Adds Two New Directors; Corporate Overview & 3Q Results Webcast Set for November 16, 2010
4. VaxGen and diaDexus Complete Merger
5. ADVENTRX Pharmaceuticals Announces Capital Raise of $22.5 Million
6. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
7. Amarin Announces Underwriters Exercise of Over-Allotment Option
8. Nonin Medical Announces Microsoft® HealthVault™ Certification of World’s First Continua™-Certified, Bluetooth® Wireless Fingertip Pulse Oximeter at CES 2011
9. Century Park Capital Partners Announces the Recapitalization of Cirtec Medical Systems, LLC
10. The Center for Business Intelligence (CBI) Announces Virtual Conference on Imaging for Drug Development
11. Vapotherm, Inc. Announces CE Mark Approval for Flowrest® Homecare Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... England , May 31, 2016 , ... global demand for its Patient Status Engine wireless patient monitoring ... India , Germany , Scotland ... , The company,s 2 nd generation system, launched earlier this ... around the world , , This new technology ...
(Date:5/30/2016)... , May 30, 2016 ... "Healthcare Analytical Testing Services Market by Type (Stability, ... Services), by End User (Pharmaceutical Companies, Medical Device ... MarketsandMarkets, The market witnessed healthy growth during the ... a CAGR of 11.3% between 2016 and 2021 ...
(Date:5/30/2016)... Eye expert s ... examination before leaving hospital ... Moorfields Eye Hospital Dubai, the first overseas branch of the world-renowned ... premature babies as a special concern in the region when it ... of prematurity (ROP). ROP is a potentially blinding condition that affects ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Joe DiMaggio Children’s ... Florida. , The clinic is led by a world class team of ... pediatric neuropsychology and also a team of certified vestibular therapists. , The ...
(Date:5/31/2016)... ... , ... RF Safe's has decades of experience in both RF shielding design ... implicated in the most recent cell phone cancer link released by NTP researchers. , ... 26th (PDF) by the National Toxicology Program (NTP), a multiagency research effort, have ...
(Date:5/31/2016)... Overland Park, Kansas (PRWEB) , ... May 31, ... ... Kansas, announces that Keith Pardoe, FDAI, DAHC, CDC, has joined the Fire Door ... for fire door inspections and fire door and frame in-field re-labeling. He ...
(Date:5/31/2016)... Barbara, CA (PRWEB) , ... May 31, 2016 , ... Throughout the day, adults often ... for sustained motivation and awareness, but what they could be reaching for instead is a ... tea plants that are grown in Japan. This sacred tea is harvested from early June ...
(Date:5/31/2016)... ... 2016 , ... Presence Technology , a multi-channel provider ... Gartner, Inc. in the Contact Center Infrastructure Magic Quadrant (*). , Gartner’s May ... of which include: Computer-telephony integration (CTI)/Web services interfaces, Tools for integration with ...
Breaking Medicine News(10 mins):